Aclaris extends former CFO Frank Ruffo's consulting term to June 30, 2023 with $12,500 monthly fee

Aclaris Therapeutics, Inc.

Consulting term extended from March 3, 2023 through June 30, 2023.
Monthly consulting fee set at $12,500 for services rendered during the term.
No outstanding equity awards will vest after March 2, 2023; vesting ceased on that date.

item 5.02

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-004698

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.